AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.08M
Average 0.32M
ACIU Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
AC Immune S.A.NASDAQ: ACIU
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 4.0% from a year ago
Cash & equivalents stood at CHF 19.17M at the end of Q1 FY2026, down 4.0% from a year earlier and down 28.5% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.
Context
- Cash & equivalents amounted to 13.9% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -4.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CHF · from the balance sheet
- Latest · FY2025
- 26.83M CHF
- Year-over-year change
- -26.0%
- 4-year CAGR
- -24.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.83M | -26.0% |
| FY2024 | 2024-12-31 | 36.28M | -53.8% |
| FY2023 | 2023-12-31 | 78.49M | +148.5% |
| FY2022 | 2022-12-31 | 31.59M | -61.6% |
| FY2021 | 2021-12-31 | 82.22M | — |
Cash & Equivalents vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -4.0% is the 6th highest of 11, against a peer median of -0.3%.
- Cash & equivalents amounts to 13.9% of total assets for ACIU, versus a peer median of 23.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $263.76M USD | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $175.21M USD | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $131.06M USD | +9.7% | -14.7% | 20.3% | |
| Mar 2026 | $90.77M USD | -24.6% | -21.3% | 25.9% | |
| Mar 2026 | $65M USD | +29.1% | -21.4% | 97.8% | |
| Mar 2026 | $36.22M USD | -42.0% | -15.6% | 89.2% | |
| Mar 2026 | $35M USD | -72.6% | -10.9% | 12.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $20.16M USD | -10.3% | +138.6% | 7.7% |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
| Mar 2026 | $8.44M USD | +68.2% | +39.9% | 7.8% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding ACIU) | — | -0.3% | -12.8% | 23.1% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 82.22M | 31.59M | 78.49M | 36.28M | 26.83M |
| Short-term Investments | 116M | 91M | 24.55M | 129.21M | 64.69M |
| Net Receivables | 975K | 408K | 15.05M | 1.1M | 681.77K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 428K | 392K | 622K | 1.1M | 0 |
| Total Current Assets | 202.63M | 128.09M | 125.15M | 171.99M | 96.83M |
| Property, Plant & Equipment (Net) | 8.03M | 7.07M | 6.88M | 8.09M | 6.54M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 50.42M | 50.42M | 50.42M | 50.42M | 50.47M |
| Long-term Investments | 0 | 0 | 361K | 0 | 584.66K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 363K | 361K | 0 | 415K | 0 |
| Total Non-current Assets | 58.81M | 57.84M | 57.66M | 58.92M | 57.59M |
| Total Assets | 261.44M | 185.94M | 182.81M | 230.91M | 154.43M |
| Account Payables | 2M | 929K | 1.68M | 2.66M | 2.07M |
| Short-term Debt | 0 | 0 | 0 | 0 | 852.97K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 138K | 0 | 83.8M |
| Other Current Liabilities | 717K | 587K | 0 | 85.06M | 3.83M |
| Total Current Liabilities | 20.03M | 11.48M | 13.58M | 100.84M | 94.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 2.34M |
| Other Non-current Liabilities | 7.1M | 3.21M | 5.77M | 13.4M | 8.66M |
| Total Non-current Liabilities | 9.44M | 5.47M | 8.6M | 17.81M | 14.69M |
| Total Liabilities | 29.46M | 16.95M | 22.17M | 118.64M | 109.49M |
| Common Stock | 1.79M | 1.8M | 2.09M | 2.23M | 2.26M |
| Retained Earnings | (200.94M) | (264.02M) | (316.2M) | (368.24M) | (439.52M) |
| Accumulated OCI | 0 | 10K | (51K) | (5K) | 7.01K |
| Other Stockholders Equity | (0) | (0) | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 231.98M | 168.99M | 160.64M | 112.27M | 44.93M |
| Total Debt | 2.91M | 2.8M | 3.5M | 5.43M | 4.55M |
| Net Debt | (79.31M) | (28.79M) | (75M) | (30.85M) | (22.28M) |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.